Framing the strategic R&D paradigm shift in Big Pharma
A content analysis of pharmaceutical annual reports
Bibliographic Data
| ID | 21696155 |
|---|---|
| Authors | Mary E Schramm (0000-0002-6017-3937, Quinnipiac University), Katie R Place (0000-0002-4930-3972, Quinnipiac University), Alexander V Laskin (0000-0003-2967-1468, Quinnipiac University) |
| Year | 2022 |
| Publication date | 2022-04-05 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Communication Management (JOURNAL) |
| Journal identifiers | ISSN: 1363-254X • E-ISSN: 1478-0852 |
| Publisher | Emerald (PUBLISHER) |
| DOI | 10.1108/jcom-05-2021-0052 |
| OpenAlex | W4220870108 |
| Language | EN |
| References cited | 48 |
Purpose Between 1985 and 2000, the six largest US pharmaceutical firms entered a very active period of partnerships with other pharmaceutical firms to expand their knowledge of biotechnology-based research and development (R&D) frameworks and to bolster the growth of their drug portfolios. The purpose of this study is to examine the annual reports published by these companies for evidence of strategic framing of these partnerships. Design/methodology/approach A content analysis method was most appropriate for this study, as it allows for analysis of a large amount of information and accurate analysis over time. Ninety-six annual reports from the six major US pharmaceutical firms (Abbott, Bristol Myers Squibb, Eli Lilly, Johnson and Johnson, Merck, and Pfizer) were coded. The final codebook included 18 categories derived from framing theory. After collection, the data were uploaded to SPSS for statistical analysis. Findings Results indicate that mention of partnerships grew considerably in depth and length over time, but companies did not consistently employ frames to describe why or how they engaged in external partnerships. Originality/value This is the first study to assess mentions of pharmaceutical firms' external efforts to build their R&D programs and drug portfolios, from the intersecting perspectives of framing theory and the resource-based view (RBV) of the firm, to illustrate how changes were communicated to shareholders during a dynamic period of change within the industry
Business · Content analysis · Economics · Management · Originality · Qualitative research · Shareholder · Social science · Sociology · Biotechnology and Related Fields · Engineering · Innovation and Knowledge Management · Pharmaceutical Economics and Policy · Marketing
Prospering in Dynamically-Competitive Environments
Environmental disclosures in the annual report
Seven Models of Framing
Prospect Theory
The Measurement of Observer Agreement for Categorical Data
Strategic investor relations management
Political Public Relations and Strategic Framing
Framing Rape
The Investor Communication Strategies of Newspaper Corporations
Pharmaceutical Firms and the Transition to Biotechnology
The evolution of the pharmaceutical industry
The role of the mass media in investor relations
Automatic vigilance
Framing
| Citation velocity | historical |
|---|---|
| Highly cited | No |